Kardigan Inc KARD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan to Present at Two September Investor Conferences
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Trading Information
- Previous Close Price
- $15.52
- Day Range
- $15.43–16.47
- 52-Week Range
- $12.36–26.76
- Bid/Ask
- $15.78 / $16.00
- Shares Outstanding
- 93.50M
- Market Cap
- $1.48B
- Volume/Avg
- 75,716 / 569,051
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.kardigan.bio
Valuation
Metric | KARD |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KARD |
|---|---|
Quick Ratio | 8.54 |
Current Ratio | 8.72 |
Interest Coverage | — |
Quick Ratio
KARD
Profitability
Metric | KARD |
|---|---|
Return on Assets (Normalized) | −46.14% |
Return on Equity (Normalized) | −1,043.97% |
Return on Invested Capital (Normalized) | −667.72% |
Return on Assets
KARD
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|^?f<Xh% | LOCK|qlbZ> | $139B | |||
| Moderna Inc MRNA | LOCK|B$!Hy$ | LOCK|pr | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#?@FB^ | LOCK|j@@$b | $94B | |||
| argenx SE ADR ARGX | LOCK|Q@%#<k | LOCK|!Yj | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<@z^%@r | LOCK|w< | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!##$@H%v | LOCK|yZf&m | $30B | |||
| Incyte Corp INCY | LOCK|>dLvt!! | LOCK|&v | $24B | |||
| BioNTech SE ADR BNTX | LOCK|sdQgx$Z | LOCK|mX | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|D^$^#bG | LOCK|f@j^# | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>f>vy$ | LOCK|%v | $15B |
United States